Novo Nordisk’s parent to purchase Catalent for $16.5bn
Novo Holdings, the parent company of Danish drugmaker Novo Nordisk, has agreed to acquire Catalent, a US-based contract development and manufacturing organisation (CDMO), for $16.5bn. Under the terms